Who is sponsoring NCT05633589?

NCT05633589 is sponsored by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

What drugs are being tested in NCT05633589?

Interventions in NCT05633589: Sc610 cell injection.

What condition does NCT05633589 study?

NCT05633589 studies Malignant Tumor of Urinary System (Disorder).

Is NCT05633589 still recruiting?

NCT05633589 is currently status unknown. Last updated 1 December 2022.

Last reviewed 2022-12-01 · How we verify

NCT05633589

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study to Evaluate Safety, Tolerance, Pharmacokinetics and Efficacy of Sc610 Injection for Treating Advanced Urinary System Tumors

Status unknown Phase 1, PHASE2 Last updated 1 December 2022

What this trial tests

Phase 1, PHASE2 trial testing Sc610 cell injection in Malignant Tumor of Urinary System (Disorder) in 45 participants. Status unknown.

Timeline

15 December 2022

Primary endpoint
30 May 2024

30 October 2024

Quick facts

Lead sponsor	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	15 December 2022
Primary completion	30 May 2024
Estimated completion	30 October 2024

Drugs / interventions tested

Sc610 cell injection — full drug profile →

Conditions studied

Malignant Tumor of Urinary System (Disorder) — all drugs for Malignant Tumor of Urinary System (Disorder) →

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Who can join

18 and older, any sex, with Malignant Tumor of Urinary System (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an phase I/IIa, open-lable, single-arm, single-dose escalation and multiple-dose extention clinical study of cell therapy designed to observe and evaluate the tolerance, the pharmacokinetic characteristics, the safety and the efficacy of Sc610 cell injection in the treatment of advanced tumor of urinary system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials

Trials by the same sponsor.

NCT07168083 — Efficacy and Safety of Sacituzumab in Patients With OCCC After Immunotherapy Progression · not yet recruiting
NCT07413497 — A Prospective Observational Clinical Study on Exploring the Value of Surgical Excision Combined With 32P Application in · not yet recruiting
NCT07461077 — Noninvasive Implantation Potential vs Morphology-Based Selection in IVF Single Blastocyst Transfer · NA · not yet recruiting
NCT07533526 — Effects of Instrument-Assisted Constant-Speed Injection Versus Manual Injection on Pain From Large-Volume Subcutaneous I · NA · not yet recruiting
NCT07408648 — A Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Thrombocytopenia Induced by Gynecological · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05633589 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Last refreshed: 1 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05633589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing